Sep. 1 at 6:19 PM
$NUVB 1. IBTROZI® (taletrectinib) — ROS1-Positive Non-Small Cell Lung Cancer (NSCLC)The company will present new subgroup analyses of pivotal data from its Phase 2 TRUST-I and TRUST-II trials. These findings will detail efficacy and safety across specific patient subgroups at:IASLC 2026 World Conference on Lung Cancer (WCLC): September 12–15, 2026, in Seoul, South Korea.European Society for Medical Oncology (ESMO) Annual Congress: October 23–27, 2026, in Madrid, Spain.Note: The FDA accepted a supplemental New Drug Application (sNDA) with updated data for IBTROZI, carrying a target action date of January 4, 2027.